Naltrexone and relapse prevention treatment for cocaine-dependent patients

Addictive Behaviors
J M SchmitzJ Grabowski

Abstract

A double-blind, placebo-controlled clinical trial examining the joint action of naltrexone (NTX) in combination with relapse prevention (RP) therapy for the treatment of cocaine dependence was conducted. Eighty-five participants who achieved initial abstinence during the intake evaluation and detoxification phase of the study were randomized into 1 of 4 combined NTX (0 vs. 50 mg) by therapy (RP vs. Drug Counseling) experimental conditions for the 12-week outpatient treatment phase of the study. A random effects regression model to test for group differences on percentage of cocaine-positive urines indicated a significant time by medication by therapy interaction, suggesting less cocaine use over time among subjects receiving RP-50 mg than those in the other conditions. No differences were found for retention or time until first cocaine-positive urine. Naltrexone was well tolerated by participants, with acceptable rates of medication compliance observed. Treatment integrity measures confirmed successful manipulation of the psychotherapy. These results are consistent with the notion that substance use in dependent patients can be reduced with a combination of coping skills training and pharmacologic treatments.

References

Aug 25, 1978·Brain Research·R A Wise
Jan 1, 1992·Journal of Substance Abuse Treatment·A T McLellanM Argeriou
Jan 1, 1991·Journal of Neural Transmission. General Section·A M MontgomeryL J Herberg
Jan 1, 1991·Psychopharmacology·W A Corrigall, K M Coen
Sep 1, 1991·The American Journal of Drug and Alcohol Abuse·K M CarrollD S Keller
Jan 1, 1989·Life Sciences·T R KostenC Morgan
Jan 1, 1969·The Journal of Nervous and Mental Disease·E H UhlenhuthL Covi
Aug 1, 1993·Journal of Consulting and Clinical Psychology·J WaltzN S Jacobson
Nov 1, 1996·Alcoholism, Clinical and Experimental Research·F K Del BocaP F Korner
Oct 13, 1998·Psychopharmacology·D HershH R Kranzler
Feb 19, 1999·Journal of Substance Abuse Treatment·D W OslinC P O'Brien

❮ Previous
Next ❯

Citations

May 2, 2003·Psychopharmacology·David H Epstein, Kenzie L Preston
Aug 10, 2007·Psychopharmacology·Joseph A SchroederEllen M Unterwald
Jan 10, 2013·Psychopharmacology·Chiara GiulianoBarry J Everitt
Oct 12, 2005·Current Psychiatry Reports·Kathleen M Carroll
Nov 26, 2003·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Wim van den Brink, Jan M van Ree
Sep 6, 2003·Pharmacology, Biochemistry, and Behavior·Mehmet SofuogluAlison Oliveto
Jan 22, 2003·Peptides·Richard J Bodnar, Maria M Hadjimarkou
Jul 30, 2008·The Behavioral and Brain Sciences·A David RedishAdam Johnson
May 20, 2004·The American Psychologist·Katie Witkiewitz, G Alan Marlatt
Jul 11, 2006·Journal of Consulting and Clinical Psychology·Vivian M GonzalezKatherine A DeLaune
Mar 13, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Diana Simmons, David W Self
Jun 6, 2013·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Sandra D ComerRichard W Foltin
Jul 1, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Gavin BartMary Jeanne Kreek
Oct 25, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Nitya Jayaram-LindströmJohan Franck
Nov 12, 2009·Substance Abuse : Official Publication of the Association for Medical Education and Research in Substance Abuse·Sarah BowenAlan Marlatt
Feb 16, 2010·Journal of Addictive Diseases·Joy M SchmitzF Gerard Moeller
Jun 5, 2013·Social Work in Public Health·Thomas M Kelly, Dennis C Daley
Apr 28, 2006·Current Opinion in Psychiatry·Frank J Vocci, Ahmed Elkashef
May 19, 2007·Addiction Biology·Antonio Preti
Jun 30, 2004·CNS Drugs·Damaris J Rohsenow
Oct 9, 2012·La Presse médicale·Nicolas Marie, Florence Noble
Mar 20, 2012·Drug and Alcohol Dependence·Angela L StottsJoy M Schmitz
Dec 28, 2010·Neuroscience and Biobehavioral Reviews·Susan Schenk
Aug 5, 2010·Child and Adolescent Psychiatric Clinics of North America·Deborah R Simkin, Severin Grenoble
Nov 18, 2009·Pharmacology & Therapeutics·Bianca Jupp, Andrew J Lawrence
Dec 9, 2008·Drug and Alcohol Dependence·Marc E MooneyJohn Grabowski
Jan 1, 2008·Drug and Alcohol Dependence·Joy M SchmitzJohn Grabowski
Aug 1, 2007·Journal of Substance Abuse Treatment·Helen M PettinatiCharles P O'Brien
Jun 5, 2007·Addictive Behaviors·Angela L StottsJohn Grabowski
Dec 19, 2006·Journal of Substance Abuse Treatment·James Shearer
Sep 29, 2015·Alcoholism, Clinical and Experimental Research·Hollis C KarolyKent E Hutchison
Jan 4, 2012·The American Journal on Addictions·Joseph TkaczCharles Ruetsch
Sep 4, 2004·Addictive Behaviors·John GrabowskiS Stevens Negus
Oct 29, 2005·European Journal of Pharmacology·Christian Heidbreder
Feb 24, 2016·The Journal of Pharmacology and Experimental Therapeutics·Sarah A SushchykJia Bei Wang
Aug 9, 2005·Pharmacology & Therapeutics·Frank Vocci, Walter Ling
Jul 13, 2016·CNS Drugs·Elias Aboujaoude, Wael O Salame

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.